| Caption | The triple combination of STB-C017, aPD-1 and aCTLA-4 prolongs overall survival |
| Source | Syntekabio, Inc. |
| Download | |
| Related Press Releases Links |
Syntekabio发表免疫肿瘤药剂STB-C017的非临床数据 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting Syntekabioが2020年AACR総会で免疫腫瘍薬STB-C017の非臨床データを発表 |